A citation-based method for searching scientific literature

James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
Times Cited: 72







List of co-cited articles
937 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
791
31

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
31


Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
423
19

Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
Jerri M Rook, Zixiu Xiang, Xiaohui Lv, Ayan Ghoshal, Jonathan W Dickerson, Thomas M Bridges, Kari A Johnson, Daniel J Foster, Karen J Gregory, Paige N Vinson,[...]. Neuron 2015
85
18

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
48
25

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
16

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
179
16

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
15

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
15

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.
Adam G Walker, Cody J Wenthur, Zixiu Xiang, Jerri M Rook, Kyle A Emmitte, Colleen M Niswender, Craig W Lindsley, P Jeffrey Conn. Proc Natl Acad Sci U S A 2015
67
16

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.
Luisa Di Menna, Max E Joffe, Luisa Iacovelli, Rosamaria Orlando, Craig W Lindsley, Jèrome Mairesse, Pierre Gressèns, Milena Cannella, Filippo Caraci, Agata Copani,[...]. Neuropharmacology 2018
55
20



An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
Darrick T Balu, Yan Li, Shunsuke Takagi, Kendall Taylor Presti, Teniel S Ramikie, Jerri M Rook, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Vadim Y Bolshakov,[...]. Neuropsychopharmacology 2016
42
21


The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
Branden J Stansley, P Jeffrey Conn. Curr Opin Pharmacol 2018
33
27

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
12

Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins.
J C Tu, B Xiao, S Naisbitt, J P Yuan, R S Petralia, P Brakeman, A Doan, V K Aakalu, A A Lanahan, M Sheng,[...]. Neuron 1999
817
11

mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.
Jennifer E Ayala, Yelin Chen, Jessica L Banko, Douglas J Sheffler, Richard Williams, Alexandra N Telk, Noreen L Watson, Zixiu Xiang, Yongqin Zhang, Paulianda J Jones,[...]. Neuropsychopharmacology 2009
173
11

Hippocampal metaplasticity is required for the formation of temporal associative memories.
Jian Xu, Marcia D Antion, Toshihiro Nomura, Stephen Kraniotis, Yongling Zhu, Anis Contractor. J Neurosci 2014
43
18


Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
11

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.
Carolina Muguruza, J Javier Meana, Luis F Callado. Front Pharmacol 2016
30
26

Disruption of prepulse inhibition in mice lacking mGluR1.
S A Brody, F Conquet, M A Geyer. Eur J Neurosci 2003
69
10

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents.
Gene G Kinney, Maryann Burno, Una C Campbell, Lisa M Hernandez, Dana Rodriguez, Linda J Bristow, P Jeffrey Conn. J Pharmacol Exp Ther 2003
182
9

Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
82
9

Deleterious GRM1 mutations in schizophrenia.
Mohammed Akli Ayoub, Dora Angelicheva, David Vile, David Chandler, Bharti Morar, Juleen A Cavanaugh, Peter M Visscher, Assen Jablensky, Kevin D G Pfleger, Luba Kalaydjieva. PLoS One 2012
45
15

Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation.
Adam G Walker, Douglas J Sheffler, Andrew S Lewis, Jonathan W Dickerson, Daniel J Foster, Rebecca K Senter, Mark S Moehle, Xiaohui Lv, Branden J Stansley, Zixiu Xiang,[...]. Neuropsychopharmacology 2017
11
63

Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Sophie Parmentier-Batteur, Peter H Hutson, Karsten Menzel, Jason M Uslaner, Britta A Mattson, Julie A O'Brien, Brian C Magliaro, Thomas Forest, Craig A Stump, Robert M Tynebor,[...]. Neuropharmacology 2014
70
10



Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
Y Iwata, S Nakajima, T Suzuki, R S E Keefe, E Plitman, J K Chung, F Caravaggio, M Mimura, A Graff-Guerrero, H Uchida. Mol Psychiatry 2015
64
10

Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function.
Max E Joffe, Chiaki I Santiago, Julie L Engers, Craig W Lindsley, P Jeffrey Conn. Mol Psychiatry 2019
27
25

Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia.
Daya S Gupta, Robert E McCullumsmith, Monica Beneyto, Vahram Haroutunian, Kenneth L Davis, James H Meador-Woodruff. Synapse 2005
121
9

ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.
Mikhail Kalinichev, Mélanie Rouillier, Francoise Girard, Isabelle Royer-Urios, Bruno Bournique, Terry Finn, Delphine Charvin, Brice Campo, Emmanuel Le Poul, Vincent Mutel,[...]. J Pharmacol Exp Ther 2013
69
10

Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.
Julie L Engers, Alice L Rodriguez, Leah C Konkol, Ryan D Morrison, Analisa D Thompson, Frank W Byers, Anna L Blobaum, Sichen Chang, Daryl F Venable, Matthew T Loch,[...]. J Med Chem 2015
40
17

Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors.
S A Brody, S C Dulawa, F Conquet, M A Geyer. Mol Psychiatry 2004
115
8

Schizophrenia.
Jim van Os, Shitij Kapur. Lancet 2009
8

Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function.
G Mannaioni, M J Marino, O Valenti, S F Traynelis, P J Conn. J Neurosci 2001
337
8

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
207
8

Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.
Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E Browne, Jason M Uslaner, Matthew J Davis,[...]. J Pharmacol Exp Ther 2014
49
12

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
Joanna M Wierońska, Katarzyna Stachowicz, Francine Acher, Tomasz Lech, Andrzej Pilc. Psychopharmacology (Berl) 2012
54
11

Glutamate receptor ion channels: structure, regulation, and function.
Stephen F Traynelis, Lonnie P Wollmuth, Chris J McBain, Frank S Menniti, Katie M Vance, Kevin K Ogden, Kasper B Hansen, Hongjie Yuan, Scott J Myers, Ray Dingledine. Pharmacol Rev 2010
8

Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk.
S M Saini, S G Mancuso, Md S Mostaid, C Liu, C Pantelis, I P Everall, C A Bousman. Transl Psychiatry 2017
34
17







Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.